Irbesartan/Hct Eg

Irbesartan, the active ingredient in Irbesartan/HCT Eg, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is combined with hydrochlorothiazide, a thiazide diuretic, to treat hypertension in adult patients by lowering elevated blood pressure and reducing cardiovascular risk.

GNH USA supplies Irbesartan/HCT Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/HCT Eg is used in the management of hypertension, a condition characterized by chronically elevated arterial pressure. - Hypertension: provides effective blood‑pressure reduction and helps achieve target levels in patients with primary or essential hypertension.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pressure sensation. - Fatigue: reduced energy or tiredness. - Increased urination: due to diuretic action. - Electrolyte imbalance: changes in potassium or sodium levels. - Mild gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure requiring medical attention. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: dangerously high potassium levels. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Blood dyscrasias: rare blood cell abnormalities.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: regularly assess to avoid excessive lowering. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolyte surveillance: check potassium and sodium levels periodically. - Hepatic impairment: use with caution in severe liver disease. - Elderly patients: start at lower doses and monitor for orthostatic symptoms. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/HCT Eg may interact with several medicines; awareness helps prevent adverse outcomes. Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin blockade can cause severe hypotension and renal impairment. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Lithium: increased lithium levels leading to toxicity. - ACE inhibitors or other ARBs: additive effect on blood pressure and renal function. - NSAIDs: may blunt antihypertensive effect and worsen kidney function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may require dose adjustment to prevent excessive hypotension. - CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can increase irbesartan plasma concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce irbesartan effectiveness. - Diuretics that affect potassium: monitor serum potassium levels. - Antidiabetic agents: potential enhancement of hypoglycemic effect.